Harbor Capital Advisors’s Maravai LifeSciences MRVI Stock Holding History

Harbor Capital Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19K	Hold	3,060	–	–	﹤0.01%	862
2026 Q1	$9K	Buy	3,060 +1,150	+60%	+$3.9K	﹤0.01%	1012
2025 Q4	$6K	Sell	1,910 -33	-2%	-$111	﹤0.01%	1100
2025 Q3	$6K	Sell	1,943 -2,114	-52%	-$5.4K	﹤0.01%	1118
2025 Q2	$10K	Buy	4,057 +951	+31%	+$2K	﹤0.01%	976
2025 Q1	$7K	Buy	3,106 +880	+40%	+$3.48K	﹤0.01%	1085
2024 Q4	$12K	Buy	2,226 +261	+13%	+$1.68K	﹤0.01%	916
2024 Q3	$16K	Buy	+1,965	New	+$17K	﹤0.01%	858
2023 Q3	–	Sell	-3,807	Closed	-$47.3K	–	575
2023 Q2	$47.3K	Buy	+3,807	New	+$51.4K	0.01%	501

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Harbor Capital Advisors's MRVI Position: Q2 2026 in Review

Harbor Capital Advisors held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 3,060 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #862.

Harbor Capital Advisors first reported a position in MRVI in Q2 2023 and has held it in 9 quarters since. The position peaked at $47.3K in Q2 2023. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Harbor Capital Advisors held 3,060 shares of Maravai LifeSciences worth $19K as of Q2 2026.
Harbor Capital Advisors left its Maravai LifeSciences share count unchanged in Q2 2026.
Maravai LifeSciences made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #862 holding.
Harbor Capital Advisors first reported a position in Maravai LifeSciences in Q2 2023 and has held it in 9 quarters since.
Harbor Capital Advisors's Maravai LifeSciences position peaked at $47.3K in Q2 2023.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.